ÃÛÌÒÊÓÆµ

Life Sciences

  • August 13, 2025

    NC Businessman Nabs Early Exit From Investment Fraud Suit

    A businessman accused of helping launder money for a lab owner in an investment fraud scheme had no duty to disclose his dealings with the allegedly sham operation, a North Carolina Business Court judge has ruled in dismissing investors' claims against him.

  • August 12, 2025

    Judge, Terumo Attorney Spar Over 'Final Judgment' Case

    A Colorado Appeals Court judge and an attorney for Terumo disagreed strongly on the interpretation of a Colorado Supreme Court ruling that could impact a now-dismissed class action against the medical equipment sterilization company in which a man alleges the district court incorrectly forbade him from filing an amended complaint.

  • August 12, 2025

    9th Circ. Reverses Trade Secrets Striking In Biotech Suit

    The Ninth Circuit found Tuesday that a lower court prematurely struck certain trade secrets from a DNA sequencing analysis company's lawsuit alleging a competing business swiped its customer database, marketing plan and other business materials.

  • August 12, 2025

    Texas Says Eli Lilly Offered Nursing Services As Kickbacks

    Texas sued Eli Lilly & Co. Inc. on Monday in state court, accusing the drugmaker of offering kickbacks in the form of administrative services to healthcare providers via illegal marketing and quid pro quo arrangements to push its most popular drugs.

  • August 12, 2025

    Worker's Flu Shot Ruling Goes Too Far, 5th Circ. Dissent Says

    A Fifth Circuit judge on Monday said a woman briefly suspended from Texas Children's Hospital over her refusal to get a flu vaccine should be able to pursue her religious discrimination suit even though the hospital ultimately accommodated her beliefs.

  • August 12, 2025

    Biogen Says It Owes Nothing After $122M IP Royalties Mistrial

    Biogen MA Inc. urged a California federal judge to rule that it owes Genentech Inc. nothing in royalties related to expired patents, saying Genentech's argument for a $122 million award relies on "linguistic gymnastics," in a rare post-mistrial arrangement that will see the judge step in to deliver the verdict.

  • August 12, 2025

    AstraZeneca, Stockholders Far Apart In Merger Damages Tally

    Syntimmune Inc. stockholders and Alexion Pharmaceuticals have landed tens of millions of dollars apart in new tallies of interest owed after a Court of Chancery ruling in June that Alexion failed a "best efforts" duty to fulfill an autoimmune drug candidate deal.

  • August 12, 2025

    Bayer Bets $1.3B On Kumquat Cancer Drug Candidate

    Pharmaceutical company Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, on Tuesday announced that they have entered into an exclusive global license and collaboration agreement under which Kumquat will receive up to $1.3 billion to help develop and commercialize its pancreatic cancer-focused drug candidate.

  • August 12, 2025

    FTC Skeptical Of 'Partial' Sale For GTCR Merger Fix

    The Federal Trade Commission told an Illinois federal court that enforcers are reviewing an offer by private equity firm GTCR BC Holding to sell parts of a medical device coatings company in order to fix concerns raised by the company's planned purchase of Surmodics, but said a full sale is preferable.

  • August 12, 2025

    Roche Settles Trade Secrets Suit With Stanford And Profs

    Subsidiaries of F. Hoffmann-La Roche AG have settled claims with a competing startup founded by Stanford University professors to resolve claims of trade secret theft related to cancer detection technology.

  • August 11, 2025

    Abbott Shakes Suit Over Meta, Google Data Sharing For Now

    An Illinois federal judge has tossed a proposed class action accusing Abbott Laboratories of unlawfully sharing website visitors' personal data with Meta and Google, finding that the plaintiffs had failed to adequately allege that the medical device provider divulged any individually identifiable health information.

  • August 11, 2025

    GTCR Says Sale, Market Nix FTC Med Tech Merger Concerns

    Private equity firm GTCR BC Holdings urged an Illinois federal judge not to block its planned $627 million purchase of a medical device coatings company, arguing in a brief made public Friday that a planned divestiture fully resolves Federal Trade Commission concerns.

  • August 11, 2025

    Aetna, CVS Want Lab's $21M Payment Suit Tossed For Good

    Aetna and its parent company, CVS Health Corp., said a medical laboratory can't stand in the shoes of patients who were allegedly denied coverage by the insurer for lab tests, and they have asked a Connecticut federal judge to toss the lab's lawsuit for good.

  • August 11, 2025

    Judge Rules NYC Can Enforce Kava Cafe Shutdowns

    A Manhattan federal judge has ruled that New York City public health and safety officials were within their authority to issue shutdown orders to restaurants that served kava, a federally unregulated psychoactive plant derivative.

  • August 11, 2025

    Apple Prevails In Heartbeat Patent Suit On Standing, Invalidity

    A New York federal judge has tossed a New York University cardiologist's lawsuit alleging an Apple Watch feature that monitors and detects irregular heartbeats infringes his patent, siding with a magistrate judge's finding that he lacks standing and the patent is invalid.

  • August 11, 2025

    Judge OKs Becton Dickinson's $9M Investor Settlement

    A New Jersey federal judge on Monday granted the final green light to a $9 million deal that will end shareholder derivative claims that the top brass of medical tech manufacturer Becton Dickinson tried to hide regulatory problems regarding sales of its Alaris pump.

  • August 11, 2025

    SEC Says Biotech Investor Traded On Inside Info About Deal

    The U.S. Securities and Exchange Commission has filed suit against a Texas-based individual investor, accusing him of insider trading on stocks by buying shares of a public biotech firm ahead of its 2020 merger with a privately held biotechnology company.

  • August 08, 2025

    Trump Admin Threatens To Take Harvard's Patents

    The U.S. Department of Commerce on Friday threatened to invoke the government's so-called march-in rights to take control of patents owned by Harvard University, accusing the Ivy League institution of not meeting its obligations tied to federally funded research.

  • August 08, 2025

    MSN Calls On Full Fed. Circ. To Rethink Double Patenting Rule

    MSN Laboratories urged the full Federal Circuit on Friday to reconsider a decision on when patents can be invalidated for double patenting, arguing in a Parkinson's disease drug case that the court has improperly limited the free use of expired patents and permitted harassing lawsuits.

  • August 08, 2025

    How Patent Attys Can Limit 'Skinny Label' Risks In Ads

    The Federal Circuit has twice cited a company's marketing practices to allow arguments that a generic drug's "skinny label" could induce patent infringement, and here, Law360 offers tips on how patent attorneys can take a more active role in making sure company and client advertisements pass muster.

  • August 08, 2025

    GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal

    British pharmaceutical company GlaxoSmithKline said Friday it stands to make up to $500 million from settlements between German biotech companies CureVac and BioNTech after their legal disputes were squashed by a merger.

  • August 08, 2025

    FTC Maintains Support For Right-To-Repair In Med Robot Case

    The Federal Trade Commission is providing important backing for a surgical repair company's Ninth Circuit bid to revive claims accusing Intuitive Surgical of blocking third parties from refurbishing components for its popular da Vinci surgery robot, in an amicus brief suggesting defending right-to-repair work remains important for the Republican-controlled agency.

  • August 08, 2025

    Trump EO Requires Appointee Oversight Of US Grantmaking

    President Donald Trump has issued an executive order requiring that all funding opportunity announcements and grant awards be reviewed by his political appointees and allowing for grants to be terminated that fall outside the administration's priorities. 

  • August 08, 2025

    NJ Nonprofit Says Foundation Trying To Take Over Business

    A nonprofit organization that trains law enforcement officers and educators to teach children about the dangers of drugs and violence has sued the foundation that provides its curriculum, alleging that the foundation is attempting to put it out of business.

  • August 08, 2025

    Pa. Pharmacy To Pay $825K To Resolve False Claims Case

    A Pennsylvania pharmacy has agreed to pay $825,000 to resolve claims that it defrauded Medicare, the latest in a recent string of such settlements in the Eastern part of the state, according to the Philadelphia-based U.S. Attorney's Office.

Expert Analysis

  • Series

    My Opera And Baseball Careers Make Me A Better Lawyer

    Author Photo

    Though participating in opera and the world of professional baseball often pulls me away from the office, my avocations improve my legal career by helping me perform under scrutiny, prioritize team success, and maintain joy and perspective at work, says Adam Unger at Herrick Feinstein.

  • Opinion

    Subject Matter Eligibility Test Should Return To Preemption

    Author Photo

    Subject matter eligibility has posed challenges for patentees due to courts' arbitrary and confusing reasoning, but adopting a two-part preemption test could align the applicant, the U.S. Patent and Trademark Office and the courts, says Manav Das at McDonnell Boehnen.

  • 8 Ways Lawyers Can Protect The Rule Of Law In Their Work

    Author Photo

    Whether they are concerned with judicial independence, regulatory predictability or client confidence, lawyers can take specific meaningful actions on their own when traditional structures are too slow or too compromised to respond, says Angeli Patel at the Berkeley Center of Law and Business.

  • Is SEC Moving Away From Parallel Insider Trading Cases?

    Author Photo

    The U.S. Securities and Exchange Commission's apparent lack of follow-up in four recent criminal cases of insider trading brought by the Justice Department suggests the SEC may be reconsidering the expense and effort of bringing parallel civil charges for insider trading, say attorneys at Dentons.

  • Rising Enforcement Stakes For Pharma Telehealth Platforms

    Author Photo

    Two pieces of legislation recently introduced in Congress could transform the structure and promotion of telehealth arrangements as legislators increasingly scrutinize direct-to-consumer advertising platforms, potentially paving the way for a new U.S. Food and Drug Administration policy with bipartisan support, say attorneys at Sheppard Mullin.

  • Series

    Law School's Missed Lessons: Communicating With Clients

    Author Photo

    Law school curricula often overlook client communication procedures, and those who actively teach this crucial facet of the practice can create exceptional client satisfaction and success, says Patrick Hanson at Wiggam Law.

  • 3 Judicial Approaches To Applying Loper Bright, 1 Year Later

    Author Photo

    In the year since the U.S. Supreme Court overturned Chevron deference in its Loper Bright Enterprises v. Raimondo decision, a few patterns have emerged in lower courts’ application of the precedent to determine whether agency actions are lawful, say attorneys at Husch Blackwell.

  • Prepping For SEC's Changing Life Sciences Enforcement

    Author Photo

    By proactively addressing several risk areas, companies in the life sciences sector can position themselves to minimize potential exposure under the U.S. Securities and Exchange Commission's return to back-to-basics enforcement focused on insider trading and fraud, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From US Rep. To Boutique Firm

    Author Photo

    My transition from serving as a member of Congress to becoming a partner at a boutique firm has been remarkably smooth, in part because I never stopped exercising my legal muscles, maintained relationships with my former colleagues and set the right tone at the outset, says Mondaire Jones at Friedman Kaplan.

  • How Providers Can Brace For Drug Pricing Policy Changes

    Author Photo

    Though it's uncertain which provisions of the Trump administration's executive order aimed at addressing prescription drug costs will eventually be implemented, stakeholders can reduce potential negative outcomes by understanding pathways that could be used to effectuate the order's directives, say attorneys at McDermott.

  • Discretionary Denial Rulings May Spur Calls For PTAB Reform

    Author Photo

    The U.S. Patent and Trademark Office's recent decision in iRhythm Technologies v. Welch Allyn, denying inter partes review based on the patent owner's settled expectations that the patent would not be challenged, could motivate patent holders to seek Patent Trial and Appeal Board reform to preserve patent quality without burdening owners, say attorneys at Dechert.

  • Comparing New Neural Data Privacy Laws In 4 States

    Author Photo

    Although no federal law yet addresses neural privacy comprehensively, the combined effect of recent state laws in Colorado, California, Montana and Connecticut is already shaping the regulatory future, but a multistate compliance strategy has quickly become a gating item for those experimenting with neuro-enabled workplace tools, says Kristen Mathews at Cooley.

  • Spinoff Transaction Considerations For Biotech M&A

    Author Photo

    Amid current market challenges, boards and management teams of biotech companies can consider several strategies for maximizing value should a spinoff opportunity arise, but not without significant advance planning and careful implementation, particularly in cases that might qualify as tax-free, say attorneys at Paul Hastings.

  • Opinion

    Senate's 41% Litigation Finance Tax Would Hurt Legal System

    Author Photo

    The Senate’s latest version of the Big Beautiful Bill Act would impose a 41% tax on the litigation finance industry, but the tax is totally disconnected from the concerns it purports to address, and it would set the country back to a time when small plaintiffs had little recourse against big defendants, says Anthony Sebok at Cardozo School of Law.

  • Psychedelic Treatment Regs May Be At A Tipping Point

    Author Photo

    Recent scientific and public attention suggest that development of psychedelics as treatment for some conditions may be at a tipping point, which could bring on more rapid change and opportunities for stakeholders who may in the future benefit from greater access to safe and effective psychedelic medicines, say attorneys at King & Spalding.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.